Kymera Therapeutics, Inc.
- Last sale
- Nov 12, 2026 · -5.84%
- Market cap
- $10.85B
- 85.37M shares
- Filings
- 647
Q3 2026−16.7% FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026derivedN/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026+196.9% FY25 yoy
- $10.85B
- —
- 106.2×
- 6.7×
- -2.66%
- —
Twelve months to Sep 30, 2026 · derived
Price
Nov 12, 2026 · IEX last sale
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $39,211,000 | reported | |
| FY 2024 | 2024-12-31 | $47,072,000 | reported | |
| FY 2023 | 2023-12-31 | $78,592,000 | reported | |
| FY 2022 | 2022-12-31 | $46,826,000 | reported | |
| FY 2021 | 2021-12-31 | $72,832,000 | reported | |
| FY 2020 | 2020-12-31 | $34,034,000 | reported | |
| FY 2019 | 2019-12-31 | $2,934,000 | reported |
Biological products, except diagnostic substances
Kymera Therapeutics, Inc. is the 49th largest of the 176 covered companies the SEC files under this code, by revenue. SIC 2836
CompanyRevenueGrowthNet marginMarket cap
BSEMBioStem Technologies, Inc.$47.5M31.8%13.9%$24.7MFENCFennec Pharmaceuticals Inc.$44.6M6.1%21.8%$381.4MCHRSCoherus Oncology, Inc.$42.2M59.8%398.4%$83.4MEDITEditas Medicine, Inc.$40.5M25.4%395.0%$329.5MVYGRVoyager Therapeutics, Inc.$40.4M49.5%296.5%$105.8MSGMOQSangamo Therapeutics, Inc$39.6M31.6%310.8%$49.7M
KYMRKymera Therapeutics, Inc. (this company)$39.2M16.7%794.0%$10.9B
CCCCC4 Therapeutics, Inc.$35.9M1.0%292.1%$405.1MXFORX4 Pharmaceuticals, Inc$35.1M1,273.2%225.6%$324.2MPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Kymera Therapeutics, Inc. · CIK 1815442 · Engraved from SEC EDGAR